MX2011011754A - Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. - Google Patents
Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.Info
- Publication number
- MX2011011754A MX2011011754A MX2011011754A MX2011011754A MX2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- complement protein
- antibodies targeting
- targeting complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de enlace de antígeno de los mismos, que se enlazan a la proteína de complemento C3b tanto humana como de cinomolgo, así como a composiciones y métodos de uso de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17586009P | 2009-05-06 | 2009-05-06 | |
PCT/EP2010/056129 WO2010136311A2 (en) | 2009-05-06 | 2010-05-05 | Compositions and methods for antibodies targeting complement protein c3b |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011754A true MX2011011754A (es) | 2011-11-29 |
Family
ID=43063291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011754A MX2011011754A (es) | 2009-05-06 | 2010-05-05 | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20100291106A1 (es) |
EP (1) | EP2427491A2 (es) |
JP (1) | JP2012525829A (es) |
KR (1) | KR20120088551A (es) |
CN (1) | CN102459334A (es) |
AR (1) | AR076655A1 (es) |
AU (1) | AU2010252156A1 (es) |
CA (1) | CA2760757A1 (es) |
CL (1) | CL2011002756A1 (es) |
CO (1) | CO6440515A2 (es) |
EA (1) | EA201101593A1 (es) |
EC (1) | ECSP11011445A (es) |
IL (1) | IL216061A0 (es) |
MA (1) | MA33402B1 (es) |
MX (1) | MX2011011754A (es) |
PE (1) | PE20120899A1 (es) |
SG (1) | SG175432A1 (es) |
TN (1) | TN2011000528A1 (es) |
TW (1) | TW201043638A (es) |
UY (1) | UY32612A (es) |
WO (1) | WO2010136311A2 (es) |
ZA (1) | ZA201107551B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
ES2523640T3 (es) | 2006-06-21 | 2014-11-28 | Musc Foundation For Research Development | Direccionamiento del factor H del complemento para el tratamiento de enfermedades |
ME01699B (me) | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Metode za stimulaciju regeneracije jetre |
MX2012005151A (es) | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
MX2012013233A (es) | 2010-05-14 | 2013-05-20 | Univ Colorado Regents | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. |
KR20130036276A (ko) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 보체 결합 3의 C3d 조각에 대한 항체들 |
CN103261893A (zh) * | 2010-11-29 | 2013-08-21 | 诺沃姆德治疗公司 | 用于诊断组织损害的新抗体 |
US9243060B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized anti-factor C3b antibodies and uses thereof |
JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
CN110818798A (zh) * | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
CA2892748A1 (en) * | 2012-11-29 | 2014-06-05 | Bayer Healthcare Llc | Humanized monoclonal antibodies against activated protein c and uses thereof |
US20160051673A1 (en) | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
EA034870B1 (ru) | 2013-08-07 | 2020-03-31 | Алексион Фармасьютикалз, Инк. | Белковые биомаркеры атипичного гемолитического уремического синдрома |
CA2926812A1 (en) * | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
AU2014370404A1 (en) | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
SG11201606983SA (en) | 2014-02-27 | 2016-09-29 | Allergan Inc | COMPLEMENT FACTOR Bb ANTIBODIES |
WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
CA3093356A1 (en) * | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
EP4257602A3 (en) * | 2018-06-11 | 2023-12-27 | Aarhus Universitet | Single domain antibodies for complement regulation |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
CN117295766A (zh) * | 2021-03-19 | 2023-12-26 | 艾佩斯瑞生物制药公司 | 对唾液酸结合性ig样凝集素15具特异性的抗体及其用途 |
KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
WO2024064732A2 (en) * | 2022-09-20 | 2024-03-28 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO2001084149A2 (en) * | 2000-04-29 | 2001-11-08 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
US7838165B2 (en) * | 2004-07-02 | 2010-11-23 | Kabushiki Kaisha Toshiba | Carbon fiber synthesizing catalyst and method of making thereof |
US20090004183A1 (en) * | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
AU2005311101B8 (en) * | 2004-12-02 | 2011-03-03 | Domantis Limited | Anti-IL-IRI single domain antibodies and therapeutic uses |
RS56677B1 (sr) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitela dobijenih hucal gold tehnologijom, specifičnih za humani cd38 |
GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
RU2473563C2 (ru) * | 2007-06-07 | 2013-01-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ |
CL2008003241A1 (es) * | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
-
2010
- 2010-05-04 US US12/773,246 patent/US20100291106A1/en not_active Abandoned
- 2010-05-05 TW TW099114417A patent/TW201043638A/zh unknown
- 2010-05-05 PE PE2011001908A patent/PE20120899A1/es not_active Application Discontinuation
- 2010-05-05 AU AU2010252156A patent/AU2010252156A1/en not_active Abandoned
- 2010-05-05 MA MA34415A patent/MA33402B1/fr unknown
- 2010-05-05 AR ARP100101527A patent/AR076655A1/es not_active Application Discontinuation
- 2010-05-05 EP EP10747599A patent/EP2427491A2/en not_active Withdrawn
- 2010-05-05 JP JP2012509035A patent/JP2012525829A/ja active Pending
- 2010-05-05 CA CA2760757A patent/CA2760757A1/en not_active Abandoned
- 2010-05-05 CN CN201080026538XA patent/CN102459334A/zh active Pending
- 2010-05-05 EA EA201101593A patent/EA201101593A1/ru unknown
- 2010-05-05 SG SG2011080330A patent/SG175432A1/en unknown
- 2010-05-05 MX MX2011011754A patent/MX2011011754A/es not_active Application Discontinuation
- 2010-05-05 WO PCT/EP2010/056129 patent/WO2010136311A2/en active Application Filing
- 2010-05-05 KR KR1020117029046A patent/KR20120088551A/ko not_active Application Discontinuation
- 2010-05-06 UY UY0001032612A patent/UY32612A/es not_active Application Discontinuation
-
2011
- 2011-10-14 ZA ZA2011/07551A patent/ZA201107551B/en unknown
- 2011-10-19 TN TNP2011000528A patent/TN2011000528A1/en unknown
- 2011-10-31 IL IL216061A patent/IL216061A0/en unknown
- 2011-11-04 CO CO11150255A patent/CO6440515A2/es not_active Application Discontinuation
- 2011-11-04 CL CL2011002756A patent/CL2011002756A1/es unknown
- 2011-11-08 EC EC2011011445A patent/ECSP11011445A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010136311A3 (en) | 2011-05-26 |
AR076655A1 (es) | 2011-06-29 |
CA2760757A1 (en) | 2010-12-02 |
IL216061A0 (en) | 2012-01-31 |
MA33402B1 (fr) | 2012-07-03 |
WO2010136311A2 (en) | 2010-12-02 |
CL2011002756A1 (es) | 2012-03-23 |
KR20120088551A (ko) | 2012-08-08 |
UY32612A (es) | 2010-12-31 |
CN102459334A (zh) | 2012-05-16 |
TN2011000528A1 (en) | 2013-05-24 |
EA201101593A1 (ru) | 2012-06-29 |
CO6440515A2 (es) | 2012-05-15 |
EP2427491A2 (en) | 2012-03-14 |
JP2012525829A (ja) | 2012-10-25 |
PE20120899A1 (es) | 2012-08-03 |
TW201043638A (en) | 2010-12-16 |
US20100291106A1 (en) | 2010-11-18 |
ECSP11011445A (es) | 2012-01-31 |
AU2010252156A1 (en) | 2011-11-10 |
ZA201107551B (en) | 2012-07-25 |
SG175432A1 (en) | 2011-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
PH12013502205A1 (en) | Antibodies to il-6 and their uses | |
PH12014502527B1 (en) | St2 antigen binding proteins | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
MX2021001494A (es) | Anticuerpos dkk1 y metodos de uso. | |
PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
MY166776A (en) | Humanised anti-ctla4 antibodies | |
MX2013005015A (es) | Anticuerpos anti-il-23. | |
EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
MX2009006471A (es) | Anticuerpo anti especifico de linfopoyetina estromal timica de diseño. | |
MX2010008688A (es) | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. | |
UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
UA107490C2 (uk) | TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
WO2011004028A3 (en) | Tlr3 binding agents | |
MA34004B1 (fr) | Protéines de liaison à cd127 | |
JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
MY170404A (en) | Antigen binding proteins | |
TN2011000041A1 (en) | Compositions and methods for antibodies targeting complement protein c5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |